The Chinse drug administration approved Chongqing Lummy Pharmaceutical's (SHE:300006) supplementary application for alanyl glutamine injection's two specifications, according to a Shenzhen Stock Exchange disclosure on Tuesday.
The approval covers 50 milliliters: 10 grams and 100ml:20g.
The drug is suitable for parenteral nutrition of patients who need glutamine supplementation, including those with catabolic and hypermetabolic conditions, the pharmaceutical company said.
Lummy's shares jumped more than 8% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。